EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Perspective for Discovery of Small Molecule IL-6 Inhibitors through Study of Structure–Activity Relationships and Molecular Docking

Hossam Nada, Aneesh Sivaraman iD, Qili Lu, Kyoungho Min, Sungdo Kim, Ja-Il Goo, Yongseok Choi, Kyeong Lee iD

Journal of Medicinal Chemistry · 13.04.2023 · 66 (7) · 4417-4433

DOI: 10.1021/acs.jmedchem.2c01957 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 27.03.2023. Verfasst von Hossam Nada und 7 weiteren Autor:innen. Beteiligte Einrichtung: BK21 FOUR Team and Integrated Research Institute for Drug Development, College of Pharmacy, Dongguk University, Seoul, Goyang 10326, Republic of Kore…. Hauptthemen laut MEDLINE: COVID-19, Autoimmune Diseases. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 144 Literaturangaben. Gefördert von: Ministry of Education, National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Interleukin-6 (IL-6) is a proinflammatory cytokine that plays a key role in the pathogenesis and physiology of inflammatory and autoimmune diseases, such as coronary heart disease, cancer, Alzheimer's disease, asthma, rheumatoid arthritis, and most recently COVID-19. IL-6 and its signaling pathway are promising targets in the treatment of inflammatory and autoimmune diseases. Although, anti-IL-6 monoclonal antibodies are currently being used in clinics, huge unmet medical needs remain because of the high cost, administration-related toxicity, lack of opportunity for oral dosing, and potential immunogenicity of monoclonal antibody therapy. Furthermore, nonresponse or loss of response to monoclonal antibody therapy has been reported, which increases the importance of optimizing drug therapy with small molecule drugs. This work aims to provide a perspective for the discovery of novel small molecule IL-6 inhibitors by the analysis of the structure-activity relationships and computational studies for protein-protein inhibitors targeting the IL-6/IL-6 receptor/gp130 complex.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Autoimmune DiseasesHumansInterleukin-6 InhibitorsMolecular Docking SimulationAntibodies, MonoclonalInterleukin-6Structure-Activity Relationship

Substanzen

Interleukin-6 InhibitorsAntibodies, MonoclonalInterleukin-6

Autor:innen und Institutionen

  • BK21 FOUR Team and Integrated Research Institute for Drug Development, College of Pharmacy, Dongguk University, Seoul, Goyang 10326, Republic of Korea.
  • College of Life Sciences and Biotechnology, Korea University, Seoul 02841, Republic of Korea.

ORCID-Profile: Aneesh Sivaraman, Kyeong Lee

Förderung

  • Ministry of Education
  • National Research Foundation of Korea

Zitieren

APA

Nada, H., Sivaraman, A., Lu, Q., Min, K., Kim, S., Goo, J. I., Choi, Y., & Lee, K. (2023). Perspective for Discovery of Small Molecule IL-6 Inhibitors through Study of Structure–Activity Relationships and Molecular Docking. Journal of Medicinal Chemistry, 66(7), 4417-4433. https://doi.org/10.1021/acs.jmedchem.2c01957

Vancouver

Nada H, Sivaraman A, Lu Q, Min K, Kim S, Goo JI, et al. Perspective for Discovery of Small Molecule IL-6 Inhibitors through Study of Structure–Activity Relationships and Molecular Docking. Journal of Medicinal Chemistry. 2023;66(7):4417-4433. doi:10.1021/acs.jmedchem.2c01957

BibTeX
@article{Nada2023,
  author = {Nada, Hossam and Sivaraman, Aneesh and Lu, Qili and Min, Kyoungho and Kim, Sungdo and Goo, Ja-Il and Choi, Yongseok and Lee, Kyeong},
  title = {Perspective for Discovery of Small Molecule IL-6 Inhibitors through Study of Structure–Activity Relationships and Molecular Docking},
  journal = {Journal of Medicinal Chemistry},
  year = {2023},
  volume = {66},
  number = {7},
  pages = {4417--4433},
  doi = {10.1021/acs.jmedchem.2c01957}
}
Kostenlos starten →